Hong Kong stock anomaly | Lai Kai Pharmaceuticals-B (02105.HK) now up nearly 6% New generation PI3K inhibitor and WRN inhibitor independently developed included in AACR 2025.

According to the Zhitong financial APP, Lai Kai Pharmaceuticals-B (02105.HK) is now up nearly 6%, as of the time of publication, it is up 5.86%, at 14.46 Hong Kong dollars, with a trading volume of 17.1235 million Hong Kong dollars.